Open-label pilot study (N = 10) of two supervised oral psilocybin sessions combined with a 12-session MET behavioural intervention for alcohol dependence, assessing feasibility, safety, and preliminary drinking outcomes.
Open-label, single-group Phase II pilot administering two all-day oral psilocybin sessions (0.3 and 0.4 mg/kg, 4 weeks apart) alongside a 12-week manualised Motivational Enhancement Therapy programme including preparation and debriefing.
Outcomes include drinking behaviour and potential mediators (motivation, self-efficacy, craving), mood and anxiety measures, spiritual dimensions, safety and adverse events, with follow-up to 24 weeks post-treatment.
Two supervised oral psilocybin administration sessions combined with a 12-session manualised outpatient psychosocial intervention (MET) over 12 weeks.
Two doses (0.3 mg/kg and 0.4 mg/kg) given in separate all-day sessions 4 weeks apart; delivered with 12-session MET including preparation and debriefing.
This open-label pilot study (n=10) of psilocybin-assisted treatment of alcohol dependence (21mg/70kg) presents a qualitative content analysis of the 17 debriefing sessions conducted in the pilot study, which occurred the day after corresponding psilocybin medication sessions. Participants articulated a series of key phenomena related to change in drinking outcomes and acute subjective effects of psilocybin.